Ketamine Therapy Blog — Mental Health Insights & Treatment Guides
Expert insights on ketamine therapy, depression, anxiety, PTSD, and mental health treatment — updated regularly by the Isha Health clinical team.
The Neuroplasticity Window: What to Do After Ketamine
Ketamine triggers a 24-72 hour neuroplasticity window through BDNF release. Here is a practical guide to maximizing this window for lasting mental health.
Ketamine for CRPS: A Case of Long-Term Pain Relief
A 2026 BMJ case report documents long-term relief of CRPS-associated limb dystonia with ketamine infusion. What this means for chronic pain patients.
The Montreal Model: Ketamine Therapy for Alcohol + Depression
A 2026 feasibility trial protocol combines structured ketamine therapy with psychotherapy for alcohol use disorder and treatment-resistant depression.
Group Ketamine Therapy for Identity-Based Trauma
A 2026 pilot study tested group ketamine-assisted psychotherapy for transgender adults experiencing identity-based trauma. Results showed significant improvements.
White House Accelerates Psychedelic Therapy for Serious Mental Illness: April 2026 Executive Order Explained
A physician's read on the April 2026 White House executive order accelerating psychedelic therapy for serious mental illness — what changes, what doesn't, and.
Trauma-Informed Care During Ketamine Treatment
Patients referred for ketamine therapy often have complex trauma histories. A 2026 clinical protocol outlines trauma-informed nursing practices for safe.
Ketamine and Your Gut: The Microbiome Connection
New research reveals a bidirectional relationship between ketamine and the gut microbiome. How gut bacteria may influence ketamine's antidepressant effects.
Ketamine for Depression in Older Adults with MCI
Can ketamine treat depression in older adults with mild cognitive impairment? A 2026 editorial in the American Journal of Geriatric Psychiatry examines the evidence.
Ketamine + Mindfulness for Opioid Addiction: RCT Results
A 2026 Nature Mental Health RCT found ketamine-assisted mindfulness therapy significantly reduced drug use and cravings in patients with opioid use disorder.
Psychedelic Medicine in 2026: Where We Stand
From ketamine clinics to psilocybin trials and MDMA setbacks — a physician's overview of where psychedelic medicine stands in 2026 and what's next.
6 Weeks of Oral Ketamine for TRD, PTSD, and OCD
A 2025 open-label study tested six weeks of oral ketamine for treatment-resistant depression, PTSD, and OCD. Improvements sustained across all three conditions.
Why Some Patients Respond Better to Ketamine
A pharmacogenetics pilot study explores why some patients respond better to esketamine. Genetic, clinical, and demographic variables all play a role.
Page 2 of 18
Get new articles in your inbox
Research updates and clinical insights on ketamine therapy — no spam.